Clinical Trials Browser

Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Constipation, Diarrhea, Gastrointestinal Hemorrhage, Hepatomegaly, Macroglossia, Nausea, Purpura

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Active not recruiting

1,087 enrolled

Plasma cell

Multiple Myeloma

NCT04617925 2025-09-05

EMN27

Phase 2 Completed

35 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT03896737 2025-08-11

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Phase 2 Active not recruiting

401 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT05123131 2025-07-08

Isa-RVD

Phase 2 Active not recruiting

54 enrolled

Plasma cell

Multiple Myeloma

NCT05561387 2025-06-04

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Phase 3 Recruiting

510 enrolled

Plasma cell

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Phase 3 Completed

1,085 enrolled 22 charts 1 FDA

Plasma cell

Multiple Myeloma

NCT04483739 2025-02-26

IsKia

Phase 3 Active not recruiting

302 enrolled

Plasma cell

Multiple Myeloma

NCT04564703 2025-02-25

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

Phase 2 Active not recruiting

160 enrolled

Plasma cell

Multiple Myeloma

NCT03683277 2025-02-19

IFM2014-01

Phase 2 Terminated

26 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Genetic Diseases, Inborn

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

103 enrolled

Plasma cell

Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

14 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT05944783 2025-02-12

BE-Dasatinib

Phase 4 Not yet recruiting

46 enrolled

Plasma cell

Multiple Myeloma

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Phase 2 Completed

143 enrolled 14 charts

Plasma cell

Multiple Myeloma, Recurrence

NCT01857115 2024-11-13

wCCyd

Phase 1/2 Completed

63 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT04934475 2024-11-07

MIDAS

Phase 3 Active not recruiting

791 enrolled

Plasma cell

Multiple Myeloma

NCT06183489 2024-10-18

ERASMM

Phase 2 Recruiting

50 enrolled

Plasma cell

Smoldering Multiple Myeloma

NCT06189833 2024-04-23

TAURUS

Phase 2 Unknown

200 enrolled

Plasma cell

Multiple Myeloma

NCT04144387 2024-03-06

CARRISMM

Phase NA Active not recruiting

395 enrolled

Plasma cell

Smoldering Multiple Myeloma

NCT05066607 2024-03-06

IsAMYP

Phase 2 Unknown

46 enrolled

Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT02056756 2024-02-20

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Phase 1/2 Completed

63 enrolled

Plasma cell

Multiple Myeloma

NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Phase 2 Completed

150 enrolled

Plasma cell

Disease, Multiple Myeloma

NCT01913730 2023-12-13

Maintenance Therapy With Subcutaneous Bortezomib

Phase 2 Completed

63 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT01524926 2023-12-11

CREATE

Phase 2 Completed

582 enrolled

LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

NCT04805203 2023-10-19

Covimmunomm

Phase NA Terminated

139 enrolled

Plasma cell

COVID-19, Multiple Myeloma

NCT00049673 2023-09-13

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Phase 3 Completed

332 enrolled 11 charts

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT05082675 2023-09-11

Stem Cell Translpantation in Multiple Myeloma

Phase 2 Completed

357 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01346787 2023-09-08

CCD

Phase 2 Completed

58 enrolled

Plasma cell

Multiple Myeloma

NCT02597062 2023-08-28

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Phase 2 Completed

76 enrolled 9 charts

Plasma cell

Multiple Myeloma

NCT00305812 2023-08-04

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Phase 2 Completed

51 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01145989 2023-08-04

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

8 enrolled

Plasma cell

Multiple Myeloma, Recurrence

Clinical Trials

MMRC Horizon One: RRMM (MMRC-099)

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis

EMN19

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

CPD-DARA

ElLen

CAPTUR

MajesTEC-4

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

CARTITUDE-6

Perseus

EMN14

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

DRAMMATIC

S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

EMN27

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

Isa-RVD

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Cassiopeia

IsKia

Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients

IFM2014-01

MyDRUG

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

BE-Dasatinib

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

wCCyd

MIDAS

ERASMM

TAURUS

CARRISMM

IsAMYP

Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Maintenance Therapy With Subcutaneous Bortezomib

CREATE

Covimmunomm

Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma

Stem Cell Translpantation in Multiple Myeloma

CCD

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma